GENETIC & STRUCTURAL BASIS FOR INFLUENZA VIRUS NEUTRALIZATION

基因

• 批准号: 9570367
• 负责人: James E Crowe
• 金额: $ 261.68万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-30 至 2019-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9570367
• 关键词: Affinity; Antibodies; Antibody-mediated protection; Award; B-Lymphocyte Epitopes; Biochemistry; Bioterrorism; Computer software; Contracts; Crystallization; Data; Databases; Emerging Communicable Diseases; Epitopes; Evaluation; Genetic; Human; Humoral Immunities; Immune; Immunoglobulin Variable Region; In Vitro; Influenza; Monoclonal Antibodies; Pathogenesis; Point Mutation; Protein Fragment; Proteins; Recombinant Proteins; Recombinants; Resources; Sampling; Structure; Toxin; Validation; Variant; Viral Antibodies; Virus; Zika Virus; human monoclonal antibodies; influenzavirus; multidisciplinary; nanoparticle; neutralizing monoclonal antibodies; novel; programs

The contracts awarded under this program support multi-disciplinary teams to identify novel B cell epitopes and elucidate mechanisms of antibody-mediated protection or pathogenesis that are important in humoral immunity in humans to emerging and re-emerging infectious diseases and potential agents of bioterrorism and their toxins. Each milestone-driven contract includes 1) epitope identification; 2) epitope validation that must include in vitro evaluation using human samples; 3) submission of epitope data, computer software, and structural data to the Immune Epitope Database and Analysis Resource; and 4) studies to help understand the mechanisms of protection or pathogenesis elicited by antibodies associated with the newly identified epitopes.

根据该计划授予的合同支持多学科团队鉴定新的B细胞表位，阐明抗体介导的保护机制或发病机制，这些机制在人类对新出现和再出现的传染病和潜在生物恐怖主义制剂及其毒素的体液免疫中很重要。每个里程碑驱动的合同包括：1)表位识别；2)表位验证必须包括使用人类样本的体外评估；3)提交表位数据、计算机软件和结构数据到免疫表位数据库和分析资源；4)研究与新发现的表位相关的抗体引发的保护或发病机制。